
Sign up to save your podcasts
Or


We discuss a phase 2/3 trial employing tarcocimab reformer for branch and central vein occlusion with Michael Singer, MD, Clinical Professor University of Texas San Antonio Health Sciences Center.
By Retina Synthesis4.5
88 ratings
We discuss a phase 2/3 trial employing tarcocimab reformer for branch and central vein occlusion with Michael Singer, MD, Clinical Professor University of Texas San Antonio Health Sciences Center.

18 Listeners

2,445 Listeners

112,683 Listeners

673 Listeners

56,469 Listeners

595 Listeners

4 Listeners

11 Listeners

52 Listeners

10 Listeners

18 Listeners

1 Listeners

0 Listeners

708 Listeners